Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her expertise provides essential understanding for anyone interested in the complexities of lung cancer

FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy for EGFR+ NSCLC

The US Food and Drug Administration (FDA) approved a new treatment option for people diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Prior to this approval, treatment with osimertinib alone was the gold-standard targeted therapy for this population. The recent approval offers another option to patients – the combination of osimertinib with chemotherapy. This FDA approval is based on the results of the FLAURA 2 phase III clinical trial, which demonstrated that the addition of chemotherapy to

Lung Cancer Masterclass: Get Smart About Lung Cancer

In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient. These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements. Each year, LUNGevity offers a free virtual conference, the International Lung Cancer Survivorship Conference, or ILCSC, to

Questions to Ask About Clinical Trials

Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic questions to ask and get answered before making a decision are: Do you know of any clinical trials for my type and stage of lung cancer? What are the benefits and risks of this clinical trial? What are the eligibility guidelines? How long does the study last? Will you still be in charge of my care? What are the costs, and what will my insurance cover? Are there other people I can talk to about this study, or a place I

Clinical Trial Phases

The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments. Phases of a Clinical Trial: 1. Safety of the new treatment 2. Does the cancer respond to the treatment 3. Is this new treatment better than the current options 4. Studies the long-term benefits and side effects

What Is a Clinical Trial

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts.

Watch Recorded Expert Sessions From ILCSC

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23. The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are available until December 21. The recordings provide opportunities for attendees to hear from world-renowned

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S. Food and Drug Administration (FDA) recently issued a draft guidance outlining recommendations and important

Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care

Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled to welcome our panelists: Balazs Halmos, MD, a thoracic medical oncologist from Montefiore Medical Center in New York; Elizabeth Ravera, a patient navigator at Montefiore; and a patient living with lung cancer who tested positive for the ALK biomarker. The panel is moderated by LUNGevity's Amy Moore, PhD, VP of Global Engagement and Patient Partnerships. This webinar is co-sponsored by LUNGevity Foundation and Amgen.